Table 1.
Descriptive statistics of patients providing tumor for models. FSL-Frozen section lab, which is the primary point of surgical material procurement.
| Engraftment still under assessment (Censored) | Engrafted | Failed Engraftment | All | p-value (engrafted vs. failed) | |
|---|---|---|---|---|---|
|
| |||||
| Patient age at collection, years median (range) | 62 (39–89) | 64 (29–91) | 62 (22–85) | 63 (22–91) | 0.77 |
|
| |||||
| Time (hours) from FSL to mouse, median (range) | 1.7 (1.1–2.8) | 1.7 (0.9–3.6) | 1.8 (0.9–7.3) | 1.7 (0.9–7.3) | 0.85 |
|
| |||||
| Morphology | |||||
| Serous | 15 (63%) | 111 (66%) | 24 (53%) | 150 (64%) | 0.018 |
| Mucinous | 2 (8%) | 2 (1%) | 2 (4%) | 6 (3%) | |
| Endometrioid | 1 (4%) | 11 (7%) | 6 (13%) | 18 (8%) | |
| Clear Cell | 1 (4%) | 10 (6%) | 1 (2%) | 12 (5%) | |
| Mixed | 3 (13%) | 23 (14%) | 4 (9%) | 30 (13%) | |
| Undifferentiated | 0 | 1 (1%) | 1 (2%) | 2 (1%) | |
| Brenner | 0 | 0 | 1 (2%) | 1 (<1%) | |
| Carcinosarcoma | 0 | 6 (4%) | 2 (4%) | 8 (3%) | |
| Other | 2 (8%) | 3 (2%) | 4 (9%) | 7 (3%) | |
|
| |||||
| Timing of Surgery | |||||
| Primary | 19 (73%) | 145 (86%) | 37 (82%) | 201 (84%) | 0.31 |
| Interval Debulking | 0 (0%) | 4 (2%) | 0 (0%) | 4 (2%) | |
| Recurrent | 7 (27%) | 19 (11%) | 8 (18%) | 34 (14%) | |
|
| |||||
| Stage | |||||
| I–II | 4 (21%) | 35 (24%) | 15 (41%) | 54 (27%) | 0.049 |
| III–IV | 15 (79%) | 109 (76%) | 22 (59%) | 146 (73%) | |
|
| |||||
| Tumor Grade | |||||
| Borderline | 1 (6%) | 1 (1%) | 4 (11%) | 6 (3%) | 0.00087 |
| Low | 4 (22%) | 14 (10%) | 7 (20%) | 25 (13%) | |
| High | 13 (72%) | 119 (89%) | 24 (69%) | 156 (83%) | |
|
| |||||
| Ascites | |||||
| Present | 8 (44)% | 77 (58%) | 9 (26%) | 94 (51%) | 0.00091 |
| Absent | 10 (56%) | 55 (42%) | 25 (74%) | 90 (49%) | |